What Makes This Biotech A “Strong Buy”? An Underappreciated – And Potentially Transformative – Late-Stage Pipeline

The biotech featured in today’s article “selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology, and provide an opportunity to be first-to-market or offer a significant benefit over existing products” – and when it comes to his “Strong Buy” rating for the stock, the author points to two drug candidates in the company’s late-stage pipeline that he believes are underappreciated by investors and that could be transformative to the company’s growth profile. For more, CLICK HERE.